These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28644504)

  • 1. A structural mechanism of flavonoids in inhibiting serine proteases.
    Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
    Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
    Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
    Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
    Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
    J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
    J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
    Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
    Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis.
    Islam I; Yuan S; West CW; Adler M; Bothe U; Bryant J; Chang Z; Chu K; Emayan K; Gualtieri G; Ho E; Light D; Mallari C; Morser J; Phillips G; Schaefer C; Sukovich D; Whitlow M; Chen D; Buckman BO
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3372-3375. PubMed ID: 30201291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
    West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
    Spencer JR; McGee D; Allen D; Katz BA; Luong C; Sendzik M; Squires N; Mackman RL
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2023-6. PubMed ID: 12113833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of multicentered short hydrogen bond arrays to potency of active site-directed serine protease inhibitors.
    Katz BA; Spencer JR; Elrod K; Luong C; Mackman RL; Rice M; Sprengeler PA; Allen D; Janc J
    J Am Chem Soc; 2002 Oct; 124(39):11657-68. PubMed ID: 12296731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
    Al-Sha'er MA; Khanfar MA; Taha MO
    J Mol Model; 2014 Jan; 20(1):2080. PubMed ID: 24469103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
    Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
    Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition activities of natural products on serine proteases.
    Jedinák A; Maliar T; Grancai D; Nagy M
    Phytother Res; 2006 Mar; 20(3):214-7. PubMed ID: 16521112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
    Zhou Y; Wu J; Xue G; Li J; Jiang L; Huang M
    Biophys J; 2022 Oct; 121(20):3940-3949. PubMed ID: 36039386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.